These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 9699888)
1. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. Bocan TM; Mueller SB; Brown EQ; Lee P; Bocan MJ; Rea T; Pape ME Atherosclerosis; 1998 Jul; 139(1):21-30. PubMed ID: 9699888 [TBL] [Abstract][Full Text] [Related]
2. F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. Junquero D; Bruniquel F; N'Guyen X; Autin JM; Patoiseau JF; Degryse AD; Colpaert FC; Delhon A Atherosclerosis; 2001 Mar; 155(1):131-42. PubMed ID: 11223434 [TBL] [Abstract][Full Text] [Related]
3. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802 [TBL] [Abstract][Full Text] [Related]
4. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Bocan TM; Mazur MJ; Mueller SB; Brown EQ; Sliskovic DR; O'Brien PM; Creswell MW; Lee H; Uhlendorf PD; Roth BD Atherosclerosis; 1994 Nov; 111(1):127-42. PubMed ID: 7840808 [TBL] [Abstract][Full Text] [Related]
5. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Bocan TM; Krause BR; Rosebury WS; Lu X; Dagle C; Bak Mueller S; Auerbach B; Sliskovic DR Atherosclerosis; 2001 Jul; 157(1):97-105. PubMed ID: 11427208 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of acyl-CoA cholesterol O-acyltransferase reduces the cholesteryl ester enrichment of atherosclerotic lesions in the Yucatan micropig. Bocan TM; Mueller SB; Uhlendorf PD; Brown EQ; Mazur MJ; Black AE Atherosclerosis; 1993 Mar; 99(2):175-86. PubMed ID: 8503946 [TBL] [Abstract][Full Text] [Related]
7. ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Krause BR; Pape ME; Kieft K; Auerbach B; Bisgaier CL; Homan R; Newton RS Arterioscler Thromb; 1994 Apr; 14(4):598-604. PubMed ID: 8148358 [TBL] [Abstract][Full Text] [Related]
8. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Nicolosi RJ; Wilson TA; Krause BR Atherosclerosis; 1998 Mar; 137(1):77-85. PubMed ID: 9568739 [TBL] [Abstract][Full Text] [Related]
9. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. Bocan TM; Mueller SB; Uhlendorf PD; Newton RS; Krause BR Arterioscler Thromb; 1991; 11(6):1830-43. PubMed ID: 1931885 [TBL] [Abstract][Full Text] [Related]
10. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Alfon J; Guasch JF; Berrozpe M; Badimon L Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960 [TBL] [Abstract][Full Text] [Related]
11. Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters. Nakamura S; Kamiya S; Shirahase H; Kanda M; Yoshimi A; Tarumi T; Kurahashi K Arzneimittelforschung; 2004; 54(2):102-8. PubMed ID: 15038459 [TBL] [Abstract][Full Text] [Related]
12. The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. Bocan TM; Mueller SB; Mazur MJ; Uhlendorf PD; Brown EQ; Kieft KA Atherosclerosis; 1993 Aug; 102(1):9-22. PubMed ID: 8257456 [TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Krause BR; Newton RS Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869 [TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Liang K; Kim CH; Vaziri ND Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547 [TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Martínez-González J; Alfón J; Berrozpe M; Badimon L Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203 [TBL] [Abstract][Full Text] [Related]
16. Phytoconstituents of an ethanolic pod extract of Prosopis cineraria triggers the inhibition of HMG-CoA reductase and the regression of atherosclerotic plaque in hypercholesterolemic rabbits. Ram H; Jaipal N; Charan J; Kashyap P; Kumar S; Tripathi R; Singh BP; Siddaiah CN; Hashem A; Tabassum B; Abd Allah EF Lipids Health Dis; 2020 Jan; 19(1):6. PubMed ID: 31931807 [TBL] [Abstract][Full Text] [Related]
17. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Vaziri ND; Liang K Am J Physiol Renal Physiol; 2004 Nov; 287(5):F1038-43. PubMed ID: 15280162 [TBL] [Abstract][Full Text] [Related]
18. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Mitani H; Egashira K; Kimura M Pharmacol Res; 2003 Nov; 48(5):417-27. PubMed ID: 12967585 [TBL] [Abstract][Full Text] [Related]
19. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609 [TBL] [Abstract][Full Text] [Related]
20. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Bocan TM; Rosebury WS; Mueller SB; Kuchera S; Welch K; Daugherty A; Cornicelli JA Atherosclerosis; 1998 Feb; 136(2):203-16. PubMed ID: 9543090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]